Icon Wealth Advisors LLC Makes New $2.47 Million Investment in AstraZeneca PLC $AZNCF

Icon Wealth Advisors LLC acquired a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the 4th quarter, HoldingsChannel reports. The fund acquired 14,094 shares of the company’s stock, valued at approximately $2,473,000.

Several other institutional investors also recently bought and sold shares of the business. Saranac Partners Ltd acquired a new position in shares of AstraZeneca during the third quarter worth $876,000. Mascoma Wealth Management LLC acquired a new position in shares of AstraZeneca during the fourth quarter worth $46,000. Valley Wealth Managers Inc. acquired a new position in shares of AstraZeneca during the fourth quarter worth $144,000. Hendley & Co. Inc. acquired a new position in shares of AstraZeneca during the fourth quarter worth $11,373,000. Finally, L & S Advisors Inc acquired a new position in shares of AstraZeneca during the fourth quarter worth $14,863,000. 40.87% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Price Performance

OTCMKTS AZNCF opened at $187.10 on Friday. The company’s fifty day simple moving average is $187.10 and its 200-day simple moving average is $185.98. AstraZeneca PLC has a 52 week low of $122.26 and a 52 week high of $195.00.

AstraZeneca Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.